Test Price
2,600 AED✅ Home Collection Available
Next-Generation Sequencing: Alexander Disease Test in Dubai
Executive Summary & Core Metrics
- ✓ Price: 2,600 AED (all-inclusive: home collection, cold-chain transport, NGS sequencing with Sanger confirmation, bioinformatics analysis, and post-test telephonic clinical guidance).
- ✓ Turnaround Time: 40 working days (approximately 8 weeks) from sample receipt at our ISO 9001:2015 accredited laboratory (Cert: INT/EGQ/2509DA/3139).
- ✓ Accuracy Guarantee: 99.9% diagnostic sensitivity via NGS with orthogonal Sanger confirmation, ensuring definitive molecular diagnosis for Alexander disease.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all seven emirates.
- ✓ Post-Test Guidance: Complimentary telephonic clinical guidance from a DHA-licensed genetics professional for comprehensive result interpretation.
- ✓ Insurance: Direct billing verification via WhatsApp at +971 54 548 8731 — our team confirms coverage before your appointment.
Test Overview & Methodology
The Alexander Disease NGS Test is a comprehensive genetic analysis targeting GFAP gene mutations responsible for this rare neurodegenerative disorder. The methodology employs next-generation sequencing with orthogonal Sanger confirmation to achieve 99.9% diagnostic accuracy. This ISO 9001:2015 certified test provides definitive molecular diagnosis for patients presenting with spasticity, seizures, macrocephaly, and developmental delays, enabling precise clinical management, genotype-phenotype correlation, and comprehensive family genetic counseling in accordance with UAE genetic testing regulations.
| Parameter | Our Test — Alexander Disease NGS | Closest Alternative — Standard NGS Panel |
|---|---|---|
| Methodology | NGS + Orthogonal Sanger Sequencing Confirmation | NGS Only (no orthogonal confirmation) |
| Diagnostic Sensitivity | 99.9% | ~95% (potential false positives/negatives) |
| Turnaround Time | 40 Working Days (8 Weeks) | 60–90 Working Days (12–18 Weeks) |
| Certification | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable / Unverified |
| Pre-Test Consent | Form 37 Mandatory (UAE-Compliant Genetic Counseling) | Often Omitted |
| Post-Test Guidance | Included — Telephonic Clinical Guidance | Not Included |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh — Consultant Medical Genetics, DHA Registration ID: 9294403
"The NGS Alexander Disease Test provides critical genetic confirmation of GFAP mutations, yet results must always be correlated with clinical presentation. A positive finding establishes the molecular diagnosis, but disease severity and progression vary considerably among patients, even within the same pedigree. I strongly advise all individuals and their families to undergo comprehensive pre-test and post-test genetic counseling to fully understand inheritance patterns, recurrence risks, and reproductive options. This test is performed under strict UAE regulatory oversight and our ISO 9001:2015 quality framework."
⚠ Medication Advisory
Do not discontinue prescribed medications without consulting your treating physician. Genetic test results complement clinical management and are not a substitute for ongoing medical supervision. Abrupt cessation of anti-epileptic drugs or muscle relaxants may precipitate serious adverse events, including status epilepticus or severe spasticity crises.
⚠ Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed Without Clinical Clearance):
- Patient is hemodynamically unstable or currently admitted to intensive care
- Incomplete or unsigned Whole Exome Sequencing Consent Form (Form 37)
- Sample collected in incorrect tube type (must be Lavender Top EDTA — no heparin, no serum separator)
- Previously frozen sample (frozen whole blood compromises DNA integrity — strictly refrigerated transport only)
- Patient has undergone allogeneic bone marrow transplantation within the past 90 days (donor DNA may confound results)
Emergency Red Flags — Seek Immediate Medical Attention:
- Status epilepticus or prolonged seizures lasting more than 5 minutes
- Acute loss of consciousness or unresponsiveness
- Severe respiratory distress or apnea episodes
- Sudden severe spasticity with complete loss of mobility
- Signs of raised intracranial pressure: severe headache, vomiting, blurred vision, altered mental status
- Acute dysphagia with risk of aspiration
If you or the patient experience any of the above red-flag symptoms, proceed immediately to the nearest emergency department. Do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the Alexander Disease NGS Test and who should consider it?
The Alexander Disease NGS Test analyzes the GFAP gene to definitively confirm or exclude Alexander disease in symptomatic patients. This test is specifically indicated for infants and children presenting with macrocephaly, developmental regression, spasticity, and seizure disorders, as well as adults with atypical neurological symptoms suggestive of the later-onset form. It is also used for carrier status determination in asymptomatic siblings of confirmed cases, with mandatory parental or legal guardian consent and genetic counseling as required by UAE regulations.
2. How is the sample collected and what is the turnaround time for results?
A certified phlebotomist collects 10 mL of whole blood via our ISO-certified cold-chain home collection service for maximum convenience. The sample is drawn into two Lavender Top (EDTA) tubes, immediately refrigerated (never frozen), and transported under strict cold-chain protocols to our ISO 9001:2015 accredited laboratory. A signed Whole Exome Sequencing Consent Form (Form 37) is mandatory. The report is delivered within 40 working days (approximately 8 weeks), reflecting the rigorous NGS sequencing, bioinformatics analysis, and Sanger confirmation required for 99.9% diagnostic accuracy. Our VIP mobile phlebotomy team serves all seven emirates daily from 8 AM to 11 PM.
3. Is the Alexander Disease NGS Test covered by health insurance in the UAE?
Insurance coverage varies by provider, but our team offers direct billing verification via WhatsApp (+971 54 548 8731) before your appointment. Many UAE medical insurance plans, including those under the DHA mandatory health insurance scheme and Thiqa (Abu Dhabi), provide partial or full coverage for medically indicated genetic testing when accompanied by a referral from a DHA-licensed neurologist or pediatrician. We recommend contacting our insurance verification team before scheduling to confirm your specific plan's coverage and any pre-authorization requirements. For patients without insurance, the test is available at a transparent all-inclusive price of 2,600 AED.
UAE Regulatory & Data Privacy Adherence
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All patient genomic data, test results, and personally identifiable health information are encrypted, stored securely within UAE-based servers, and processed in strict accordance with UAE PDPL requirements. No data is transferred outside the UAE without explicit patient consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: This facility adheres to all provisions governing the secure handling, storage, and transmission of electronic health data, including genomic sequencing results and associated clinical metadata.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: All clinical testing, patient consent procedures, and post-test guidance are conducted in full compliance with this law, ensuring patient safety and legal accountability throughout the diagnostic pathway.
- DHA Facility License: 1143 — Issued by Dubai Health Authority, valid and in good standing.
- Physical Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — Corporate Lab Branding: DNA Labs UAE.
- ISO 9001:2015 Certification: Cert: INT/EGQ/2509DA/3139 — Internationally recognized quality management system certification covering all pre-analytical, analytical, and post-analytical laboratory processes.
Clinical & Logistical Metadata
| Test Name | Alexander Disease NGS Test (GFAP Gene Sequencing) |
| Price (AED) | 2,600 AED (All-Inclusive) |
| Turnaround Time | 40 Working Days (8 Weeks) |
| Sample Type / Matrix | Peripheral Whole Blood (Lavender Top EDTA Tubes) |
| Methodology Used | Next-Generation Sequencing (NGS) + Orthogonal Sanger Confirmation |
| ICD-10-CM Code | G93.8 |
| LOINC Code | 82313-0 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians